Maxim Group Thinks Capricor Therapeutics’ Stock is Going to Recover


Maxim Group analyst Jason McCarthy maintained a Buy rating on Capricor Therapeutics (NASDAQ: CAPR) today and set a price target of $7. The company’s shares closed yesterday at $1.20, close to its 52-week low of $0.96.

McCarthy said:

“Capricor reported 2Q18 with a net loss of $(4.1M) and ended the period with $12.3M in cash on the balance sheet, runway into 2Q19.”

According to TipRanks.com, McCarthy is a 5-star analyst with an average return of 13.9% and a 43.8% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as SELLAS Life Sciences Group Inc, ContraVir Pharmaceuticals Inc, and Sonoma Pharmaceuticals Inc.

Capricor Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $7.80, implying a 550.0% upside from current levels. In a report released today, H.C. Wainwright also reiterated a Buy rating on the stock with a $8.60 price target.

.

See today’s analyst top recommended stocks >>

The company has a one-year high of $4.25 and a one-year low of $0.96. Currently, Capricor Therapeutics has an average volume of 239.6K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Capricor Therapeutics, Inc. engages in the discovery, development and commercialization of first-in-class biological therapies for the treatment of cardiac and other serious medical conditions. Its product candidate consists of CAP-1002, Cenderitide, Exosomes, CAP-1001, CU-NP and CSps.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts